AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24986956 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mM
Number of subjects: 0
Study 24986956 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 1 mM
Number of subjects: 0
Study 24986956 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 2 mM
Number of subjects: 0
Study 24986956 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ketamine)
Number of subjects: 0
Study 22323727 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased activation to houses in the fusiform face area (FFA) with age
Number of subjects: 300
Study 22323727 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased activation to faces in the extended face network with age
Number of subjects: 300
Study 20819400 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementation of bands using Resin cement
Number of subjects: 48
Study 20819400 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementation of bands using Resin‐modified Glass Ionomer Cement (RMGIC)
Number of subjects: 48
Study 20819400 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementation of bands using conventional Glass Ionomer Cement (GIC)
Number of subjects: 48
Study 20819400 — intervention group
Group type: COMPARATOR
Intervention: Adaptation of bands without cementation (Control group)
Number of subjects: 48
Study 19267100 — intervention group
Group type: EXPERIMENTAL
Intervention: Di Bella multitherapy
Number of subjects: 1100
Study 19267100 — intervention group
Group type: COMPARATOR
Intervention: Control (not receiving Di Bella multitherapy)
Number of subjects: 1100
Study 15667759 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in shared decision‐making skills and the use of risk communication materials
Number of subjects: 20
Study 12846601 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant orthopedics (IO) based on a modified Zurich approach in the first year of life
Number of subjects: 12
Study 12846601 — intervention group
Group type: COMPARATOR
Intervention: Non-infant orthopedics (non-IO)
Number of subjects: 12
Study 12846601 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant orthopedics (IO)
Number of subjects: 12
Study 10658277 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural anesthesia
Number of subjects: 22
Study 10658277 — intervention group
Group type: COMPARATOR
Intervention: Non-epidural anesthesia
Number of subjects: 22
Study 8673817 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrimethamine-sulphadoxine (PS)
Number of subjects: 300
Study 8673817 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 300
Study 8673817 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 300
Study 1442957 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 486 (1 mg/day orally)
Number of subjects: 11
Study 1442957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 4021969 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) treatment
Number of subjects: 0
Study 31959002 — intervention group
Group type: EXPERIMENTAL
Intervention: Menu-based health promotion implementation strategies selected by church leaders, including forming a health ministry, allocating space or budget for health activities, and including health in church communications/sermons.
Number of subjects: 3
Study 30384289 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Inoculation Training (SIT)
Number of subjects: 70
Study 30384289 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study 26971533 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib (first-line)
Number of subjects: 570
Study 26971533 — intervention group
Group type: COMPARATOR
Intervention: Imatinib (control)
Number of subjects: 570
Study 26971533 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib (second-line or later)
Number of subjects: 570
Study 25100270 — intervention group
Group type: EXPERIMENTAL
Intervention: Concrete rumination
Number of subjects: 136
Study 25100270 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstract rumination
Number of subjects: 136
Study 25100270 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstract conditions
Number of subjects: 136
Study 25100270 — intervention group
Group type: COMPARATOR
Intervention: Concrete conditions
Number of subjects: 136
Study 22570949 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg every 12 hours for 3 months)
Number of subjects: 26
Study 22570949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 22570949 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 26
Study 19952722 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative hypothermia (33.3 degrees +/- 0.8 degrees C), n = 208
Number of subjects: 441
Study 19952722 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental protective drug (thiopental or etomidate), n = 178
Number of subjects: 441
Study 19952722 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (36.7 degrees +/- 0.5 degrees C), n = 233
Number of subjects: 441
Study 17609936 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg daily
Number of subjects: 61
Study 17609936 — intervention group
Group type: COMPARATOR
Intervention: Non-steroidal anti-inflammatory drug (diclofenac 50 mg)
Number of subjects: 61
Study 16197471 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral suplatast 300 mg daily for 3 months
Number of subjects: 25
Study 16197471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 12377628 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestically manufactured low-molecular-weight heparin
Number of subjects: 60
Study 12377628 — intervention group
Group type: COMPARATOR
Intervention: Imported low-molecular-weight heparin
Number of subjects: 60
Study 10541777 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg)
Number of subjects: 24
Study 10541777 — intervention group
Group type: COMPARATOR
Intervention: Ebastine (20 mg)
Number of subjects: 24
Study 7752640 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.35 g/kg)
Number of subjects: 81
Study 7752640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 2271194 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 20 micrograms/kg
Number of subjects: 60
Study 2271194 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 10 micrograms/kg
Number of subjects: 60
Study 2271194 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 60
Study 2271194 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (both doses)
Number of subjects: 60
Study 6446106 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-hydroxymethane diphosphonate (HMDP)
Number of subjects: 102
Study 6446106 — intervention group
Group type: COMPARATOR
Intervention: 99mTc-methylene diphosphonate (MDP)
Number of subjects: 102
Study 30985632 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 900-mg oral dose of delafloxacin
Number of subjects: 460
Study 30985632 — intervention group
Group type: COMPARATOR
Intervention: Single 250-mg intramuscular ceftriaxone
Number of subjects: 460
Study 27929185 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (MEL)
Number of subjects: 0
Study 27929185 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxytyrosol (OHTyr)
Number of subjects: 0
Study 27929185 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wines
Number of subjects: 0
Study 27929185 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 25355780 — intervention group
Group type: EXPERIMENTAL
Intervention: BiV pacing at 70 b.p.m.
Number of subjects: 14
Study 25355780 — intervention group
Group type: EXPERIMENTAL
Intervention: BiV pacing at 90 b.p.m.
Number of subjects: 14
Study 25355780 — intervention group
Group type: EXPERIMENTAL
Intervention: BiV pacing at 50 b.p.m.
Number of subjects: 14
Study 24152211 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronome-paced tachypnoea (MPT) at 40 breaths/min and I:E ratio of 1:1
Number of subjects: 24
Study 24152211 — intervention group
Group type: COMPARATOR
Intervention: Incremental exercise testing (XT)
Number of subjects: 24
Study 24152211 — intervention group
Group type: COMPARATOR
Intervention: Bronchodilator treatment
Number of subjects: 24
Study 20672762 — intervention group
Group type: EXPERIMENTAL
Intervention: Akreos AO IOL (aspheric surface)
Number of subjects: 50
Study 20672762 — intervention group
Group type: COMPARATOR
Intervention: Akreos Fit IOL (spherical surface)
Number of subjects: 50
Study 19048277 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprietary blend of modified cellulose and cetylated fatty acids (Trisynex)
Number of subjects: 22
Study 16399173 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg for 5 days
Number of subjects: 301
Study 16399173 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin 500 mg for 10 days
Number of subjects: 301
Study 15592190 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc-99m sestamibi ECG-gated SPECT
Number of subjects: 29
Study 15592190 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc-99m sestamibi ECG-gated SPECT with functional data from ECG-gated acquisitions
Number of subjects: 29
Study 15592190 — intervention group
Group type: COMPARATOR
Intervention: Successful PTCA in the acute phase of MI
Number of subjects: 29
Study 11381064 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% lignocaine drop 3 minutes before tropicamide 1%
Number of subjects: 30
Study 11381064 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nonlignocaine) before tropicamide 1%
Number of subjects: 30
Study 9006374 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil/epinephrine gel
Number of subjects: 401
Study 9006374 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil gel alone
Number of subjects: 401
Study 9006374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study 8433075 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fructose (20% of carbohydrate calories, 45‐65 g day‐1 for 4 weeks)
Number of subjects: 10
Study 8433075 — intervention group
Group type: COMPARATOR
Intervention: Control diet (placebo)
Number of subjects: 10
Study 2825941 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol, terbutaline, and epinephrine (beta-agonists)
Number of subjects: 0
Study 2825941 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 0
Study 2825941 — intervention group
Group type: COMPARATOR
Intervention: Nonselective blockade
Number of subjects: 0
Study 2825941 — intervention group
Group type: COMPARATOR
Intervention: Beta 1‐selective blockade
Number of subjects: 0
Study 2825941 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta 1‐ and beta 2‐receptor stimulation
Number of subjects: 0
Study 29545046 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified mechanical percussion
Number of subjects: 120
Study 29545046 — intervention group
Group type: COMPARATOR
Intervention: Observation (control)
Number of subjects: 120
Study 27281302 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (2.7 g/d)
Number of subjects: 154
Study 25182571 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine treatment
Number of subjects: 0
Study 25182571 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 22429693 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Workshops (8 weekly sessions)
Number of subjects: 216
Study 22429693 — intervention group
Group type: COMPARATOR
Intervention: Control group (no participation in Health Workshops)
Number of subjects: 216
Study 20888307 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol 40mg b.i.d.
Number of subjects: 48
Study 20888307 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol 120mg b.i.d.
Number of subjects: 48
Study 20888307 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol 240mg b.i.d.
Number of subjects: 48
Study 20888307 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol 400mg b.i.d.
Number of subjects: 48
Study 18164939 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 42
Study 18164939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 16371580 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTA) with selective stent placement
Number of subjects: 279
Study 16371580 — intervention group
Group type: COMPARATOR
Intervention: Primary stent placement
Number of subjects: 279
Study 14650643 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthmatic subjects (n=10)
Number of subjects: 20
Study 14650643 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (n=10)
Number of subjects: 20
Study 14650643 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (asthmatic and healthy)
Number of subjects: 20
Study 11191781 — intervention group
Group type: EXPERIMENTAL
Intervention: Study 1 - Drivers' opinions on adequate, critical, and legal gaps at 40 and 80 km/h
Number of subjects: 0
Study 11191781 — intervention group
Group type: EXPERIMENTAL
Intervention: Study 2 - Judgements of distance to a leading and a following car at 80 km/h
Number of subjects: 0
Study 8653019 — intervention group
Group type: EXPERIMENTAL
Intervention: Solipid 20% S&E (lipid emulsions based on soy oil with egg lecithin or soy lecithin) administered at 1 g/kg body weight on day 1 and 2 g/kg/day on days 2-5
Number of subjects: 20
Study 1455403 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatan sulphate (DS) 2-4 mg/kg
Number of subjects: 6
Study 1455403 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatan sulphate (DS) 5-6 mg/kg
Number of subjects: 6
Study 1455403 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatan sulphate (DS) 3 mg/kg
Number of subjects: 6
Study 1455403 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatan sulphate (DS) 6 mg/kg
Number of subjects: 6
Study 1455403 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatan sulphate (DS) 3 mg/kg plus infusion of 0.6 mg kg‐1 h‐1
Number of subjects: 6
Study 1455403 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatan sulphate (DS) 5 mg/kg plus infusion of 1 mg kg‐1 h‐1
Number of subjects: 6
Study 1455403 — intervention group
Group type: COMPARATOR
Intervention: Standard unfractionated heparin (UFH)
Number of subjects: 6
Study 4014794 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 20
Study 4014794 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 20
Study 30517695 — intervention group
Group type: EXPERIMENTAL
Intervention: Altitude at 1650 m
Number of subjects: 32
Study 30517695 — intervention group
Group type: EXPERIMENTAL
Intervention: Altitude at 2590 m
Number of subjects: 32
Study 30212961 — intervention group
Group type: EXPERIMENTAL
Intervention: LED applications (intra oral with 660 nm, 12J and extraoral with 850 nm, 108J)
Number of subjects: 38
Study 30212961 — intervention group
Group type: COMPARATOR
Intervention: Control group (simulated irradiation)
Number of subjects: 38
Study 30212961 — intervention group
Group type: EXPERIMENTAL
Intervention: LED applications
Number of subjects: 38
Study 26886262 — intervention group
Group type: COMPARATOR
Intervention: Soccer Training (SG)
Number of subjects: 26
Study 26886262 — intervention group
Group type: COMPARATOR
Intervention: Resistance Training (RG)
Number of subjects: 26
Study 26886262 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 26
Study 25430452 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous adductor canal block with 0.2% ropivacaine at 5 ml/h
Number of subjects: 60
Study 25430452 — intervention group
Group type: COMPARATOR
Intervention: Continuous femoral nerve block with 0.2% ropivacaine at 5 ml/h
Number of subjects: 60
Study 25430452 — intervention group
Group type: COMPARATOR
Intervention: Both groups (adductor and femoral)
Number of subjects: 60
Study 22540635 — intervention group
Group type: EXPERIMENTAL
Intervention: CC + NAC (100 mg/d clomiphene citrate + 1.2 g/d N-acetylcysteine)
Number of subjects: 180
Study 22540635 — intervention group
Group type: COMPARATOR
Intervention: CC + Placebo (100 mg/d clomiphene citrate + placebo)
Number of subjects: 180
Study 20630595 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-VEGF agent (ranibizumab)
Number of subjects: 40
Study 17599560 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral corticosteroid treatment
Number of subjects: 0
Study 15008925 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive glass granules mixed with autologous bone chips (BG-AB group)
Number of subjects: 17
Study 15008925 — intervention group
Group type: COMPARATOR
Intervention: Autologous bone chips alone (AB group)
Number of subjects: 17
Study 11548769 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadership program
Number of subjects: 21
Study 9579850 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltitrexed ('Tomudex')
Number of subjects: 0
Study 9579850 — intervention group
Group type: COMPARATOR
Intervention: Standard 5‐fluorouracil (5‐FU) plus leucovorin (LV)
Number of subjects: 0
Study 8297690 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine retard (20 mg twice daily)
Number of subjects: 40
Study 8297690 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril (10 mg twice daily)
Number of subjects: 40
Study 8297690 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of benazepril and nifedipine
Number of subjects: 40
Study 8297690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2920133 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen
Number of subjects: 148
Study 2920133 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg dihydrocodeine
Number of subjects: 148
Study 2920133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 4405419 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose marijuana (4.8 mg Delta(9)-THC followed by 2.4 mg one hour later)
Number of subjects: 81
Study 4405419 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose marijuana (9.1 mg Delta(9)-THC followed by 4.5 mg one hour later)
Number of subjects: 81
Study 4405419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 31200349 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic and resistance exercise of moderate to vigorous intensity 3 times per week until the end of treatment, then twice per week for 10 weeks, followed by once per week for 10 weeks
Number of subjects: 73
Study 31200349 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic and resistance exercise of moderate to vigorous intensity
Number of subjects: 73
Study 28460809 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guided Inter‐Scalene Brachial Plexus Block (ISBPB) with lidocaine and epinephrine
Number of subjects: 60
Study 28460809 — intervention group
Group type: COMPARATOR
Intervention: Procedural Sedation and Analgesia (PSA) with propofol and fentanyl
Number of subjects: 60
Study 25531162 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-4997 (ASK1 inhibitor), once daily, oral administration
Number of subjects: 300
Study 25531162 — intervention group
Group type: COMPARATOR
Intervention: Standard of care therapy
Number of subjects: 300
Study 24101040 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense temozolomide (arm 2) for 6 to 12 cycles
Number of subjects: 833
Study 24101040 — intervention group
Group type: COMPARATOR
Intervention: Standard temozolomide (arm 1) for 6 to 12 cycles
Number of subjects: 833
Study 24101040 — intervention group
Group type: EXPERIMENTAL
Intervention: MGMT methylation status
Number of subjects: 833
Study 24101040 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense temozolomide (arm 2)
Number of subjects: 833
Study 20924597 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine infusion
Number of subjects: 8
Study 20924597 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 8
Study 19655403 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Hz EA
Number of subjects: 20
Study 19655403 — intervention group
Group type: COMPARATOR
Intervention: SA
Number of subjects: 20
Study 19655403 — intervention group
Group type: COMPARATOR
Intervention: MA
Number of subjects: 20
Study 19655403 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Hz TENS
Number of subjects: 20
Study 16428531 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.1% (Group 1)
Number of subjects: 4
Study 16428531 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.15% (Group 2)
Number of subjects: 4
Study 16428531 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.175% (Group 3)
Number of subjects: 4
Study 16428531 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.2% (Group 4)
Number of subjects: 4
Study 15683501 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 200 mg/day
Number of subjects: 100
Study 15683501 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg/day
Number of subjects: 100
Study 12064924 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (1,25‐dihydroxyvitamin D3; 0.25‐3.0 microg/day) alone for the first 6 months with ceredase/cerezyme at 60 IU/kg every 2 weeks during months 7‐12
Number of subjects: 29
Study 12064924 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol together with ceredase/cerezyme at 60 IU/kg every 2 weeks during months 1‐6
Number of subjects: 29
Study 12064924 — intervention group
Group type: COMPARATOR
Intervention: Enzyme only at 60 IU/kg body wt every 2 weeks
Number of subjects: 29
Study 12064924 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (calcitriol and enzyme therapy)
Number of subjects: 29
Study 10458121 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 percent topical glyceryl trinitrate ointment
Number of subjects: 43
Study 10458121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 7531326 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma testosterone (T)
Number of subjects: 320
Study 7531326 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma estradiol (E2)
Number of subjects: 320
Study 7531326 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma estrone (E1)
Number of subjects: 320
Study 7531326 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure
Number of subjects: 320
Study 2195567 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative prophylaxis with benzylpenicillin and dicloxacillin
Number of subjects: 76